Drug firm Unichem Laboratories today said it has received approval from the US health regulator for Piroxicam capsules, used in the treatment of osteoarthritis and rheumatoid arthritis, in the US market.
In a BSE filing, Unichem Laboratories said “it has received ANDA approval from the US Food and Drug Administration (USFDA) for Piroxicam Capsules USP 10mg and 20mg“.
The approved product is therapeutically equivalent to Feldene Capsules 10mg and 20mg of Pfizer Inc.
Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA).
Unichem Laboratories said the product will be commercialised from its Goa plant.
“Active Pharmaceutical Ingredient will also be made in-house at Roha API Plant,” it added.
Shares of Unichem Laboratories were trading 1.49 per cent higher at Rs 290 on BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.